MYCOBACTERIUM TUBERCULOSIS causes tuberculosis (TB)
and is one of the most successful intracellular pathogens in humans, with approximately one-third of the world's population infected (1) . The host immune response has been found to play a critical role in both control of and protective immunity against the pathogen by targeting antigens (Ags) secreted by M. tuberculosis (2) . Consequently, identification and characterization of M. tuberculosis Ags is essential to understanding host-pathogen interactions and facilitating the development of prospective vaccine candidates (2, 3) .
Dendritic cells (DCs) are potent antigen-presenting cells (APCs) that play a pivotal role in controlling immune responses to M. tuberculosis (4) . Many studies regarding the function of DCs on M. tuberculosis infection have mainly focused on the ability of these cells by interacting with M. tuberculosis or its Ags to express major histocompatability complex (MHC) class II and costimulatory molecules, including CD80 and CD86, which induce T cell proliferation (5, 6) . Immature DCs (iDCs) have the ability to capture and internalize Ags via pattern recognition receptors (PRRs), recognizing conserved molecular moieties that distinguish a broad specificity of microbial products, the so-called pathogen-associated molecular patterns (PAMPs) (6) . On PAMP ligation by PRRs, activation of appropriate immune responses to TB can be initiated to maintain well-regulated immunological homeostasis (7) . Among various PRRs, Toll-like receptors (TLRs) play a crucial role in the activation of the cellular immune response against M. tuberculosis infection (8) . Recognition of microbial components by TLRs plays a central role in whether the immune system will respond to a particular microbial infection (8) . The intracellular signal transduction activated via TLRs is initially mediated through the Toll/interleukin-1 receptor homology (TIR) domains. Activation of signaling through TIR domains results in recruitment of the adaptor molecule myeloid differentiation factor 88 (MyD88) and/or TIR domain containing adapter inducing interferon-␤ (TRIF), ultimately leads to activation of mitogen-activated protein kinases (MAPKs) and nuclear factor B (NF-B) (8) . This signaling process enables DCs to become potent APCs to initiate robust innate immunity by up-regulating the expression of surface molecules including CD80, CD86, and MHC class I and II and a number of cytokines such as interleukin (IL)-1␤, IL-6, IL-12, and tumor necrosis factor-␣ (TNF-␣), and losing endocytic/ phagocytic receptors (6) . Moreover, these mature DCs migrate to draining lymph nodes where they present these Ags and stimulate naive T lymphocytes to initiate an immune response (6). As described above, the maturation of DCs may be particularly important for the elicitation of both primary and secondary immune responses to pathogens. Recently, several studies have reported that M. tuberculosis Ags induced the maturation and activation of DCs in a TLR2-dependent manner. For example, M. tuberculosis Ags, such as Rv1196, Rv0978c, and Rv0754, recognize TLR2 and induce maturation and activation of DCs (9 -11) . In addition, DCs matured by M. tuberculosis Ags relocate to the lymph nodes, where they produce proinflammatory cytokines and the development of an adaptive immune response that includes helper (CD4 ϩ ) T cells, cytotoxic (CD8 ϩ ) T cells, ␥␦ T cells, and the production of interferon-␥ (IFN-␥) and TNF-␣ (key cytokines in immunity to TB; refs. 12, 13).
M. tuberculosis Rv0577 (also known as CFP32 and TB27.3) is a complex-restricted secreted protein absent from environmental mycobacteria but expressed during the course of infection (14) . Notably, M. tuberculosis clinical isolates appear to express more Rv0577 than laboratory-adapted M. tuberculosis strains and other M. tuberculosis complex subspecies (including the Mycobacterium bovis BCG strain; ref. 14) . Recently, CFP32 was recognized as the enzymatic mediator of M. tuberculosisspecific neutral red dye cytochemical staining, a classic test used to differentiate virulent M. tuberculosis from nontuberculous mycobacteria (15) . Moreover, native Rv0577 has been detected in the sputum of M. tuberculosis-infected individuals and may be useful as a possible diagnostic potential (14) . Furthermore, a recent study has suggested that Rv0577 is associated with the methylglyoxal detoxification pathway as a potential glyoxylase (16) , which suggests that it is a candidate target of pyrimidine-imidazoles. Although comparative analyses suggest that the rv0577 gene product may be important to the pathogenesis of M. tuberculosis and a biological function for Rv0577 has been identified, the immunological function of this protein has not been elucidated, especially its role in innate and adaptive immunity. In the present study, we investigated the molecular basis of DC maturation and functional changes induced by a novel Rv0577 protein.
MATERIALS AND METHODS

Animals
Specific pathogen-free female C57BL/6 (H-2K b and I-A b ), BALB/c (H-2K d and I-A d ), C57BL/6J TLR2-knockout mice (TLR2 Ϫ/Ϫ ; B6.129-Tlr2 tm1Kir /J), C57BL/10 TLR4 knockout mice (TLR4 Ϫ/Ϫ ; C57BL/10ScNJ), C57BL/6 OT-1 and OT-2 T-cell receptor (TCR) transgenic mice, at 5-6 wk of age were purchased from the Jackson Laboratory (Bar Harbor, ME, USA) and maintained under barrier conditions in a biohazard animal room at the Medical Research Center, Chungnam National University. The animals were fed a sterile commercial mouse diet and provided with water ad libitum. The animal experiments complied with the ethical and experiment regulations for animal care at Chungnam National University.
Animal infection study was performed in a BL-3 biohazard animal facility at Yonsei University Medical Research Center. Briefly, 6-wk-old BALB/c mice were exposed to a predetermined dose of M. tuberculosis H37Rv (ATCC27294) for 60 min in the inhalation chamber of an airborne infection apparatus (Glas-Col, Terre Haute, IN, USA) (17) . Bacteria were counted 1 d after exposure, and ϳ200 viable M. tuberculosis were found to have been delivered to the lungs. At 8 wk postinfection, 5-6 mice were euthanized, and their spleens were collected to conduct the subsequent experiments, including mixed lymphocyte reactions (MLRs). All infection-related experiments were done according to the regulation of the Yonsei University Health System Institutional Animal Care and Use Committee.
clonal Ab, anti-phosphorylated JNK monoclonal Ab, anti-JNK polyclonal Ab, anti-phosphorylated p38 monoclonal Ab, antip38 polyclonal Ab, anti-NF-B (p65) polyclonal Ab, antiphosphorylated inhibitory B-␣ (IB-␣) monoclonal Ab, anti-IB-␣ monoclonal Ab, and anti-lamin B polyclonal Ab were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). HRP-conjugated anti-mouse immunoglobulin G (IgG) Ab and HRP-conjugated anti-rabbit Ab were obtained from Calbiochem (San Diego, CA, USA), and anti-␤-actin mAb (AC-15) was purchased from Sigma. FITC-conjugated mAb to CD11c, CD62L, and IFN-␥; APC-conjugated mAb to IL-12p70; Alexa647-conjugated mAb to CCR3; PerCP-cy5.5-conjugated mAb to CD4 ϩ and CD8 ϩ ; phycoerythrin (PE)-conjugated mAb to IL-4, CD80, CD86, MHC class I, MHC class II, CD44, and CXCR3; PE-cy5-conjugated mAb to CD4 ϩ and CD8
ϩ ; and PE-cy7-conjugated mAb to IL-2 were purchased from eBioscience (San Diego, CA, USA). IL-6, IL-1␤, TNF-␣, IL-2, IL-4, and IFN-␥ enzyme-linked immunosorbent assay (ELISA) kits were obtained from eBioscience, and IL-12p70 and IL-10 ELISA kit were obtained from BD Biosciences (San Diego, CA, USA).
Expression and purification of recombinant Rv0577
To produce recombinant Rv0577 protein, the corresponding gene was amplified by PCR using M. tuberculosis H37Rv ATCC27294 genomic DNA as template and the following primers: forward, 5=-GGGCCCCATATGCCCAAGAGAAGC-GAATACAGC-3=, and reverse, 5=-GGGCCCAAGCTTCTATT-GCTGCGGTGCGGG-3=. The product of rv0577 was cut with NdeI and HindIII. Both the products were inserted into pET28a (ϩ) vector (Novagen, Madison, WI, USA), and the resultants were sequenced. The recombinant plasmids containing rv0577 were transformed into E. coli BL21 cells by heat shock for 1 min at 42°C. The overexpressed Rv0577 was prepared with slight modifications, as described previously (18) . Briefly, E. coli containing recombinant plasmid were grown at 37°C until the optical density (OD) at 600 nm was 0.4 to 0.5 and then induced with 1 mM isopropyl-d-thiogalactopyranoside (IPTG; ELPIS-Biotech, Daejeon, South Korea). The bacterial cells were then harvested by centrifugation and suspended in 20 mM Tris-HCl (pH 8.0), 0.5 M NaCl, 20 mM imidazole, and 1 mM phenylmethylsulfonyl fluoride (Sigma); and lysed by sonication. The recombinant Rv0577 was purified by nickel-nitrilotriacetic acid (Ni-NTA) agarose chromatography in accordance with the manufacturer's instructions (Qiagen, Chatsworth, CA, USA). Each purification step was analyzed by 13.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) with Coomassie brilliant blue stain and immunoblot using anti-His antibodies (Santa Cruz Biotechnology). The purified protein was pooled, concentrated, and dialyzed against phosphate-buffered saline (PBS; pH 7.4). To remove endotoxin contamination, the dialyzed recombinant protein was incubated with polymyxin B (PmB)-agarose (Sigma) for 6 h at 4°C. Lastly, purified endotoxin-free recombinant protein was filter-sterilized and frozen at Ϫ70°C. The protein concentration was estimated with the bicinchoninic acid protein assay kit (Pierce, Rockford, IL, USA) with bovine serum albumin (BSA) as the standard. Residual LPS in the Rv0577 preparation was determined using the Limulus amoebocyte lysate (LAL) test (Lonza, Basel, Switzerland), according to the manufacturer's instructions. The purity of Rv0577 was evaluated by Coomassie blue staining, silver nitrate staining, and Western blot using an anti-histidine antibody. In addition, the purity of Rv0577 was quantified by Quantity One software (Bio-Rad, Hercules, CA, USA) and calculated by dividing the intensity per square millimeter of the Rv0577-specific band by that of all the protein bands in the preparation lane.
Generation of polyclonal antibody to Rv0577
The polyclonal antibodies against Rv0577 were generated in BALB/c mice by s.c. injection of 1 mg purified Rv0577 proteins emulsified with equal volume of incomplete Freund's adjuvant (Sigma). The first immunization was carried out with incomplete Freund's adjuvant followed by 2 booster immunizations with the same procedure at 10-d intervals. The antibody titers in the serum were determined by ELISA after 2 wk postfinal immunization.
Generation and culture of DCs
Bone marrow cells isolated from C57BL/6 mice were lysed with red blood cell (RBC) lysing buffer (ammonium chloride, 4.15 g/500 ml, and 0.01 M Tris-HCl buffer, pH 7.5Ϯ2) and washed with RPMI 1640 medium. Obtained cells were plated in 6-well culture plates (10 6 cells/ml, 3 ml/well) and cultured at 37°C in the presence of 5% CO 2 using RPMI 1640 medium supplemented with 100 U/ml penicillin/streptomycin (Lonza), 10% fetal bovine serum (Lonza), 50 M mercaptoethanol (Lonza), 0.1 mM nonessential amino acid (Lonza), 1 mM sodium pyruvate (Sigma), 20 ng/ml GM-CSF, and 20 ng/ml IL-4. On d 6 or 7 of culture, nonadherent cells and loosely adherent proliferating DC aggregates were harvested for analysis or stimulation, or in some experiments they were replated into 60-mm dishes (10 6 cells/ml, 5 ml/dish). On d 6, Ͼ80% of the nonadherent cells expressed CD11c. To obtain highly purified populations for subsequent analyses, the DCs were labeled with bead-conjugated anti-CD11c mAb (Miltenyi Biotec, Bergisch Gladbach, Germany), followed by positive selection on paramagnetic columns (LS columns; Miltenyi Biotec) according to the manufacturer's instructions. The purity of the cell fraction selected was Ͼ95%.
Cytotoxicity analysis
The Rv0577 (10 g/ml) was added to cultures of isolated bone marrow-derived DCs (BMDCs) in 12-well plates (0.5ϫ10 6 cells/ml). To investigate the cytotoxic effect of Rv0577 on BMDCs, the cell-death pattern of BMDCs was analyzed after treatment with 10 g/ml Rv0577. After 24 h of treatment, harvested DCs were washed with PBS and stained by FITC-annexin V and propidium iodide (BD Biosciences). Thereafter, cytotoxicity of DCs was analyzed by FACSCanto flow cytometry (BD Biosciences).
Measurement of cytokines
A sandwich ELISA was used for detecting IL-6, IL-1␤, TNF-␣, IFN-␥, IL-4, IL-2, IL-12p70, and IL-10 in culture supernatants, as described previously (19) . Assays of cytokines in culture medium were performed as recommended by the manufacturers (eBioscience and BD Biosciences). The levels of cytokines released into culture medium were determined by measuring absorbance at 450 nm with a microplate reader. Cytokine concentrations in the samples were calculated using standard curves generated from recombinant cytokines, and the results were expressed in picograms per milliliter.
Intracellular cytokine assays
Cells were first blocked with 10% (v/v) normal goat serum for 15 min at 4°C and then stained with FITC-conjugated CD11c ϩ antibody for 30 min at 4°C. Cells stained with the appropriate isotype-matched Ig were used as negative controls. The cells were fixed and permeabilized with a Cytofix/ Cytoperm kit (BD Biosciences) used according to the manufacturer's instructions. Intracellular IL-12p70, IL-10, IL-2, IL-4, and IFN-␥ were detected with fluorescein-conjugated antibodies (BD Biosciences) in a permeation buffer. The cells were analyzed with a flow cytometry using the CellQuest (BD Biosciences) program.
Analysis of the expression of surface molecules by flow cytometry
On d 6, BMDCs were harvested, washed with PBS, and resuspended in fluorescence-activated cell sorter washing buffer (2% FBS and 0.1% sodium azide in PBS). The cells were preincubated with 0.5% BSA in PBS for 30 min and washing with PBS. The cells were stained with PE-conjugated anti-H-2Kb (MHC class I), anti-I-Ab (MHC class II), anti-CD80, and anti-CD86 along with FITC-conjugated anti-CD11c for 45 min at 4°C. Cells were washed 3 times with PBS and resuspended in 500 l PBS. The fluorescence was measured by flow cytometry, and the data were analyzed using CellQuest data analysis software.
Ag uptake ability of BMDCs by Rv0577
BMDCs (2ϫ10 5 cell) were equilibrated at 37°C or 4°C for 45 min and then pulsed with fluorescein-conjugated dextran at a concentration of 1 mg/ml. Cold staining buffer was added to stop the reaction. The cells were washed three times, stained with PE-conjugated anti-CD11c antibodies, and then analyzed with the FACSCanto. Nonspecific binding of dextran to DCs was determined by incubation of DCs with FITC-conjugated dextran at 4°C, and the resulting background value was subtracted from the specific binding values.
Confirmation of LPS-decontamination for Rv0577
To confirm the maturation of DCs induced by Rv0577 was not due to contaminating endotoxins or LPS in the protein preparations, the pretreatment with PmB (Sigma), heatdenaturation, and digestion of proteinase K (Sigma) assays were performed. DCs were preincubated with 50 g/ml PmB for 1 h at room temperature prior to treating with 100 ng/ml LPS and 10 g/ml Rv0577. For heat denaturation, LPS or Rv0577 was incubated at 100°C for 1 h. For digestion of proteinase K, LPS or Rv0577 was digested for 1 h at 37°C with soluble proteinase K at the concentration of 10 g/ml, followed by heating for 15 min at 100°C to deactivate the enzyme, and subsequently was added to BMDC cultures. After 24 h, TNF-␣ and IL-6 levels in the supernatant of BMDCs were analyzed using ELISA.
Confocal laser scanning microscopy
DCs were plated overnight on poly-l-lysine-coated glass coverslips. After treatment with Rv0577, cells were fixed in 4% paraformaldehyde, permeabilized in 0.1% Triton X-100, and then blocked with 2% BSA in PBS containing 0.1% Tween-20 (PBS/T) for 2 h before being incubated with 2% BSA in PBS/T containing anti-Rv0577 antibody for 2 h at room temperature. After washing with PBS/T, the cells were reincubated with Cy-3 conjugated secondary antibody in the dark room for 1 h, and then were stained with 1 g/ml of DAPI for 10 min at room temperature. Cell morphology and fluorescence intensity were observed using a confocal laser scanning microscope (Zeiss LSM510 Meta; Carl Zeiss Ltd, Welwyn Garden City, UK). Images were acquired using the LSM510 Meta software and processed using the LSM image examiner.
Immunoprecipitation
DCs (1ϫ10 7 ) were incubated with 10 g/ml Rv0577 for 6 h, and cell pellets were lysed with lysis buffer (10 mM Tris-HCl, pH 7.4; 1% Nonidet P-40; 0.25% sodium deoxycolate; 150 mM NaCl; 1 mM EDTA; 1 mM PMSF; 1 g/ml each aprotinin, leupeptin, and pepstatin; 1 mM Na 3 VO 4 ; and 1 mM NaF). To avoid nonspecific binding, the cell lysates were precleared by adding 50 l of normal serum (Santa Cruz Biotechnology) and 100 l of 50% protein A or G sepharose bead slurry (Invitrogen) to 1 mg of cell lysates. After the 2 h incubation at 4°C, the mixture of bead and cell lysates was centrifuged at 10,000 g for 5 min at 4°C, and the supernatant was collected for the subsequent experiment. Rv0577 (His)-, TLR2-, and TLR4-associated proteins were immunoprecipitated by incubation with protein A or G Sepharose for 24 h at 4°C after incubation with anti-rat IgG as control Ab for anti-TLR2 and anti-TLR4, anti-mouse IgG as control Ab for anti-Rv0577 (His) for 1 h at 4°C. The beads were harvested, washed, and boiled in 5ϫ sample buffer for 5 min. The proteins were separated on 10% SDS-PAGE followed by transfer of proteins to polyvinylidene difluoride membrane (Millipore, Billerica, MA, USA). The membranes were further probed with anti-TLR2, anti-TLR4, and anti-His Abs as indicated.
Immunoblotting analysis
After stimulation with 10 g/ml Rv0577, DCs were lysed in 100 l lysis buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% Triton-X100, 1 mM EDTA, 50 mM NaF, 30 mM Na 4 PO 7 , 1 mM phenylmethanesulfonyl fluoride, 2 g/ml aprotinin, and 1 mM pervanadate. Whole-cell lysate samples were resolved on SDS-polyacrylamide gels and then transferred onto a nitrocellulose membrane. The membranes were blocked in 5% skim milk and incubated with the antibody for 2 h, followed by incubation with HRP-conjugated secondary Abs for 1 h at room temperature. Epitopes on target proteins including MAPKs and NF-B recognized specifically by Abs were visualized by using the ECL advance kit (GE Healthcare, Little Chalfont, UK).
Nuclear extract preparation
Nuclear extracts from cells were prepared as follows. DCs were treated with 100 l lysis buffer [10 mM HEPES, pH 7.9; 10 mM KCl; 0.1 mM EDTA; 0.5% Nonidet P-40; 1 mM dithioreitol (DTT); and 0.5 mM PMSF] on ice for 10 min. Postcentrifugation at 4000 rpm for 5 min, the pellet was resuspended in 100 l extraction buffer (20 mM HEPES, pH 7.9; 400 mM NaCl; 1 mM EDTA; 1 mM DTT; and 1 mM PMSF) and incubated on ice for 30 min. Postcentrifugation at 12,000 rpm for 10 min, the supernatant containing nuclear extracts was collected and stored at Ϫ80°C until required.
Treatment of DCs with pharmacological inhibitors of signaling pathways
All the pharmacological inhibitors were purchased from Calbiochem. Dimethyl sulfoxide (DMSO; Sigma) was added to cultures at 0.1% (v/v) as a solvent control. DCs were washed with PBS and pretreated with inhibitors in RPMI 1640 medium containing glutamine for 1 h prior to treatment with Rv0577 for 24 h. Inhibitors were used at following concentrations: U0126, 10 M; SB203580, 20 M; SP600125, 10 M; and Bay11-7082, 20 M. In all experiments with inhibitors, a tested concentration was used after careful titration experiments assessing the viability of the DCs using MTT assay.
MLR
Responder T cells, which participate in naive T-cell reactions, were isolated using a MACS column (Miltenyi Biotec) from total mononuclear cells prepared from BALB/c mice. Both OVA-specific CD8 ϩ and CD4 ϩ T cells, responders, were obtained from splenocytes of OT-1 and OT-2 mice, respectively. These T cells were stained with 1 M carboxyfluorescein diacetate succinimidyl ester (CFSE; Invitrogen) as described previously (20) . DCs (2ϫ10 5 cells/well) treated with OVA peptide in the presence of 10 g/ml of Rv0577 for 24 h were cocultured with CFSE-stained CD8 ϩ and CD4 ϩ T cells (2ϫ10 6 ) at DC:T-cell ratios of 1:10. On 3 or 4 d of coculture, T cells were stained with PerCP-cy5.5-conjugated anti-CD4 ϩ mAb, PE-cy5-conjugated anti-CD4 ϩ mAb, PE-cy5-conjugated anti-CD8 ϩ mAb, Alexa647-conjugated anti-CCR3 mAb, or PE-conjugated anti-CXCR3 mAb and analyzed by flow cytometer. Supernatants were harvested, and the production of IFN-␥, IL-2, and IL-4 was measured by ELISA.
Analysis of the activation of effector/memory T cells
As explained above, responder T cells, which participate in allogeneic T-cell reactions, were isolated using a MACS column (Miltenyi Biotec) from total mononuclear cells prepared from M. tuberculosis-infected BALB/c mice. Staining with APC-conjugated anti-CD3 mAb (BD Biosciences) revealed that the preparation consisted mainly of CD3 ϩ cells (Ͼ95%). DCs (2ϫ10 5 cells/well) prepared from wildtype (WT), TLR2
Ϫ/Ϫ , and TLR4 Ϫ/Ϫ C57BL/6 mice were treated with Rv0577 for 24 h followed by extensive washing and were cocultured with 2 ϫ 10 6 responder allogeneic T cells (M. tuberculosis-infected T cells) at DC:T cell ratios of 1:10. On d 4 of coculture, the cells were stained with PerCP-cy5.5-conjugated anti-CD4 ϩ mAb, PerCP-cy5.5-conjugated anti-CD8 ϩ mAb, FITC-conjugated anti-CD62L mAb, and PE-conjugated anti-CD44 mAb, and analyzed by flow cytometer.
Statistical analysis
All experiments were repeated Ն3 times with consistent results. The levels of significance for comparison between samples were determined by Tukey's multiple comparison test distribution using statistical software (Prism 4.03; GraphPad, San Diego, CA, USA). The data in the graphs are expressed as means Ϯ se. Values of P Ͻ 0.05were considered to be statistically significant.
RESULTS
Purification of recombinant Rv0577 protein and cytotoxicity
Rv0577 is an M. tuberculosis complex-restricted secreted protein involved in the methylglyoxal detoxification pathway (14) . However, the immunological contribution of Rv0577, especially the effect on the maturation and functions of DCs, remains unknown.
Recombinant Rv0577 protein was therefore produced and characterized. The purity of Rv0577 was first assessed by SDS-PAGE and Western blot analysis. The purified recombinant Rv0577 protein had a molecular mass of ϳ32 kDa (Supplemental Fig. S1A ). Endotoxin content was measured by an LAL assay and was Ͻ15 pg/ml (Ͻ0.1 UE/ml) in Rv0577 preparations. Rv0577 had 96% purity when 20 g of the protein preparation was stained with silver nitrate (data not shown). We next examined the Rv0577 protein-induced cytotoxicity in DCs by treating cells with 10 g/ml Rv0577 for 24 h, then staining with anti-CD11c, annexin V, and propidium iodide to assess cell viability. As shown in Supplemental Fig.   Figure 1 . Cytokine production by Rv0577 protein-treated DCs. DCs were generated by stimulating immature DCs with 100 ng/ml LPS, or 5 or 10 g/ml Rv0577 for 24 h. A-E) Amounts of TNF-␣ (A), IL-6 (B), IL-1␤ (C), IL-10 (D), and IL-12p70 (E) in the culture supernatant was measured by ELISA. All data are expressed as means Ϯ sd (nϭ3). n.s., not significant. *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001 vs. controls. S1B, up to 10 g/ml of Rv0577 protein displayed no cellular toxicity against DCs. Notably, this suggests that recombinant Rv0577 protein was not cytotoxic to DCs and when used in concentrations Ͻ10 g/ml would not contain significant amounts of endotoxin to interfere with our studies.
Rv0577 induces the secretion of proinflammatory cytokines by DCs toward a Th1 type immune response
Previous studies have reported that DC-derived cytokines play a critical role in the polarization of T cells and in mediating inflammatory responses (21) . We therefore analyzed whether Rv0577-mediated maturation of DCs was coupled with the secretion of pro-or anti-inflammatory cytokines by stimulating DCs with various concentrations of Rv0577 (5-10 g/ml). As demonstrated in Fig. 1A -C, Rv0577 significantly stimulated DCs to secrete high levels of TNF-␣, IL-6, and IL-1␤, whereas untreated DCs secreted negligible amounts of these cytokines. We then investigated the production of IL-12p70 and IL-10, which have an important effect on the development of T cell-mediated immune responses. Unlike LPS, Rv0577 significantly induced the secretion of IL-12p70, but not IL-10 ( Fig. 1D, E) . We also analyzed the production of intracellular IL-12p70 and IL-10 in Rv0577-treated DCs. As shown in Fig. 1F , DCs treated with Rv0577 increased the percentage of IL-12p70-positive cells compared to the results obtained for untreated DCs, while no change was found in IL-10-positive cells. These results strongly suggest that Rv0577 induces the secretion of proinflammatory cytokines from DCs and these Rv0577-matured DCs may promote a Th1 type immune response.
Rv0577 induces maturation of DCs
Maturation of DCs plays a major role in mediating immune responses to mycobacteria (4) . Therefore, to investigate whether Rv0577 induces DC maturation, we first measured the expression of DC maturation markers such as CD80, CD86, and MHC classes I and II. BMDCs were cultured for 24 h in the presence of 5 or 10 g/ml Rv0577 and analyzed for the expression of surface markers. LPS was used as a positive control. As shown in Fig. 2 , Rv0577 enhanced the expression of costimulatory molecules such as CD80 and CD86, and cell surface markers such as MHC classes I and II at concentrations of 5 and 10 g/ml, suggesting that Rv0577 efficiently induces DC maturation.
Rv0577 reduces the endocytic activity of DCs
The expression of surface molecules and changes in IL-12 production show that exposure to Rv0577 leads to profound induction of the phenotypic maturation of DCs. In this study, we investigated the role of Rv0577 in the regulation of DC endocytic activity. To test whether Rv0577 protein-stimulated DCs had the reduced endocytic activity, we exposed DCs to Rv0577 in the presence of dextran-FITC and assessed the percentage of doublepositive cells (CD11c ϩ and dextran-FITC-positive). As shown in Supplemental Fig. S2 , a much lower percentage of active cells was present in LPS-treated DCs than in untreated DCs. In addition, the same was true of Rv0577-treated DCs when compared to untreated DCs. Our results showed that Rv0577-treated DCs had reduced endocytic activity, indicating more functional maturity.
Confirmation of endotoxin-free purified Rv0577 preparations
To ensure that Rv0577-induced DC maturation was not due to endotoxin or LPS contamination, the purified Rv0577 preparations were passed through a PmB-agarose column. Furthermore, we assessed LPS contamination by treatment with proteinase K or heat denaturation, which abrogated the ability of Rv0577 to trigger DC maturation (Supplemental Fig. S3A, B) . PmB treatment did not affect the viability of Rv0577, whereas that of LPS was significantly inhibited by PmB (Supplemental Fig. S3C ). These results confirmed that DC maturation was in fact induced by intact Rv0577 and not by contaminating LPS.
Rv0577 interacts with TLR2 and induced DC maturation
Pattern recognition receptors, such as TLRs, have the ability to recognize pathogen-associated molecular patterns from whole mycobacterial cells or mycobacterial cell wall components (7). Thus, we examined whether Rv0577 could be recognized by, and act through, TLRs in DCs. To identify TLRs on DCs that interact with Rv0577, WT, TLR2 Ϫ/Ϫ , and TLR4 Ϫ/Ϫ DCs were stimulated with Rv0577; then Rv0577 on the cell surface was detected with an Alexa488-conjugated anti-Rv0577 polyclonal Ab (Fig. 3A) . Anti-Rv0577 bound to the cell surface of WT and TLR4 Ϫ/Ϫ DCs but not TLR2 Ϫ/Ϫ DCs (Fig. 3B) . To confirm the interaction between Rv0577 and TLR, we performed immunoprecipitation studies with TLR2 or TLR4 and Rv0577 in DCs. Rv0577 bound to TLR2 but not TLR4 (Fig. 3C) . This observation was also confirmed by confocal microscopy. Interestingly, we found that Rv0577 interacts preferentially with WT and TLR4 Ϫ/Ϫ DCs but not TLR2 Ϫ/Ϫ DCs (Fig. 3D) . To test the ability of Rv0577 to activate DCs via TLR2, we measured the expression of surface molecules and proinflammatory cytokine production in Rv0577-treated WT, TLR2 Ϫ/Ϫ , and TLR4 Ϫ/Ϫ DCs. The expression of surface molecules (Fig. 4A) and proinflammatory cytokine secretion (Fig. 4B) were enhanced in WT or TLR4 Ϫ/Ϫ DCs by Rv0577. In contrast, these effects were strongly diminished in TLR2 Ϫ/Ϫ DCs, indicating that Rv0577 is an agonist for TLR2 in DCs.
TLRs are critical in provoking innate immune responses through the activation of signaling cascades via TIR domain-containing adaptors, such as MyD88 and TRIF (22) . MyD88 is common to all the TLRs, whereas TRIF is essential for TLR4-mediated activation of the MyD88-independent signaling pathway (22) . Thus, MyD88 and TRIF play a potential role in the control of TLR2-and TLR4-mediated signaling pathways. To investigate the importance of the MyD88-and TRIFdependent pathways in Rv0577-induced cytokine production by DCs, we compared DC-based cytokine production in WT, MyD88
Ϫ/Ϫ , and TRIF-deficient mice. Rv0577-induced production of TNF-␣, IL-6, and IL-1␤ was significantly reduced in the absence of MyD88, whereas this effect was not observed in the absence of TRIF (Fig. 4C) . These findings clearly demonstrated that Rv0577 induced DC maturation in a TLR2-dependent manner, causing increased expression of cell-surface molecules and proinflammatory cytokines.
Expression of the NF-B and MAPK pathways in Rv0577 protein-induced maturation of DCs
NF-B and MAPKs are critical factors mediating cellular responses such as innate immunity, cellular proliferation, and survival, and recent studies have suggested that NF-B and MAPKs are essential for the maturation of DCs (22, 23) . We therefore examined the activation of NF-B and MAPKs in response to Rv0577. DCs were stimulated with Rv0577 recombinant protein at a concentration of 10 g/ml, and the phosphorylation of MAPKs (including ERK1/2, p38, and JNK), the phosphorylation/degradation of IB-␣, and the nuclear translocation of p65 were analyzed over time (Fig. 5) . As shown in Fig. 5A , the Rv0577 triggered the phosphorylation of MAPKs, such as ERK1/2, p38, and JNK. In addition, we found that the Rv0577 induced the phosphorylation and degradation of IB-␣ and nuclear translocation of p65 from cytosol (Fig. 5B, C) . These results ***P Ͻ 0.001. B) DCs derived from WT, TLR2 Ϫ/Ϫ , and TLR4 Ϫ/Ϫ mice were treated with Rv0577 or LPS for 24 h. TNF-␣, IL-6, or IL-1␤ production in Rv0577-or LPS-treated DCs derived from WT, TLR2 Ϫ/Ϫ , and TLR4 Ϫ/Ϫ mice was measured by ELISA.
C) DCs derived from WT, MyD88
Ϫ/Ϫ , and TRIF Ϫ/Ϫ mice were treated with Rv0577 (10 g/ml) and Pam3 (100 ng/ml) for 24 h. TNF-␣, IL-6, or IL-1␤ production in Rv0577-or Pam3-treated DCs derived from WT, MyD88 Ϫ/Ϫ , and TRIF Ϫ/Ϫ mice was measured by ELISA. All data are expressed as means Ϯ sd (nϭ3). ***P Ͻ 0.001.
suggest that Rv0577 protein-induced DC activation might be mediated by both the NF-B and MAPK pathways.
Rv0577 induces the production of proinflammatory cytokines and the expression of costimulatory molecules through NF-B and MAPKs
Previous studies have demonstrated that activation of the NF-B and MAPK signaling pathways plays a crucial role in the maturation of DCs induced by mycobacterial Ags (13, 24) . The molecular mechanisms involved in the regulation of DCs by Rv0577 protein, however, are not yet fully understood. Thus, to elucidate the functional roles of these kinases in the activation of DCs induced by Rv0577, we used highly specific kinase inhibitors and measured Rv0577-induced proinflammatory cytokine production and costimulatory molecule expression. The cells were pretreated with a p38 inhibitor (SB203580), an ERK1/2 inhibitor (U0126), a JNK inhibitor (SP600125), or NF-B inhibitor (Bay 11-0782) for 1 h before being exposed to Rv0577. Notably, we found that these pharmacological inhibitors significantly abrogated Rv0577-induced expression of the costimulatory molecules on the surface of DCs (Fig. 6A) , and the production of proinflammatory cytokines (Fig. 6B) . From these findings, we suggest that the NF-B and MAPK signaling pathways are essential for the production of proinflammatory cytokines and the expression of DC maturation markers induced by Rv0577.
Rv0577 protein-stimulated DCs induce naive T-cell proliferation
Increased expression of the costimulatory molecules, CD80 and CD86, along with MHC classes I and II, on DCs promotes their interaction with and activation to T cells. To precisely characterize Rv0577 activity on DC and T-cell interactions, we performed a syngeneic MLR assay using OT-I TCR transgenic CD8 ϩ T cells and OT-II TCR transgenic CD4 ϩ T cells. Transgenic CFSE-labeled OVAspecific CD4 ϩ and CD8 ϩ T cells cocultured with Rv0577-treated DCs, pulsed with OVA 257-264 (Fig. 7A) or OVA 323-339 (Fig. 7B ) and proliferated to a significantly greater extent than the same T cells cocultured with DCs without Rv0577 treatment, but pulsed with OVA 257-264 or OVA 323-339 . Furthermore, naive CD4 ϩ and CD8 ϩ T cells primed with Rv0577-treated DCs produced significantly (PϽ0.05-0.01) higher IFN-␥ and IL-2 levels than those with untreated DCs, whereas the comparable level of IL-4 secretion was detected regardless of Rv0577 stimulation (Fig.  7C) . We then investigated the expression of chemokine receptor CXCR3 and CCR3, which are associated with T-cell polarization, in CD4 ϩ T cells using flow cytometry. CXCR3 is known to be expressed at a high level on Th1 cells, whereas Th2 cells up-regulate the expression of CCR3 (25) . As shown in Fig. 7D, CD4 ϩ T cells cocultured with Rv0577-treated DCs, pulsed with OVA 323-339 showed a significant increase in the expression of CXCR3 compared to those cocultured with DCs pulsed with OVA 323-339 only, whereas no alteration in the expression of CCR3 by Rv0577 was investigated. These results suggest that the Rv0577-treated DCs direct naive T-cell proliferations toward a Th1 phenotype.
Rv0577 induces the development of effector/memory T cells via TLR2-mediated DC activation
To assess whether the maturation of DCs by Rv0577 is reflected in their ability to specifically stimulate CD4 ϩ and CD8 ϩ T cells from M. tuberculosis-infected mice, we analyzed the surface expression of CD62L and CD44 on CD4 ϩ and CD8 ϩ splenic T cells using flow cytometry. Naive T cells were previously reported to express a CD62L high CD44 low phenotype, whereas effector/memory T cells exhibit a CD44 high CD62L low phenotype (26) . CD4 ϩ and CD8 ϩ splenic T cells from M. tuberculosis-infected mice were cocultured with Rv0577-treated DCs derived from WT, TLR2 Ϫ/Ϫ , or TLR4 Ϫ/Ϫ mice. The Rv0577-treated WT and TLR4 Ϫ/Ϫ DCs specifically induced the formation of effector/memory T cells by displaying significantly down-regulated CD62L and up-regulated CD44 expression in CD4 ϩ and CD8 ϩ splenic T cells from M. tuberculosis-infected mice compared to control DCs, Pam3-treated DCs, and LPS-treated DCs, while such an effect of Rv0577 was abrogated in TLR2 Ϫ/Ϫ DCs (Fig. 8A) . In addition, the percentages of CD4-IFN-␥/ CD4-IL-2 and CD8-IFN-␥/CD8-IL-2 double-positive cells among T cells cocultured with Rv0577-WT or TLR4 Ϫ/Ϫ DCs were higher than that of those cocultured with untreated DCs, Pam3-pulsed DCs, or LPSpulsed DCs, whereas the elevation of theses cytokines was not observed in T cells cocultured with Rv0577-treated TLR2 Ϫ/Ϫ DCs (Fig. 8B) . In addition, IL-4 expression of CD4 ϩ T cells among T cells treated with Rv0577-pulsed DCs, Pam3-pulsed DCs, or LPS-pulsed DCs remained at baseline levels (Fig. 8B) . These data suggest that Rv0577-mediated DC activation induces the development of effector/memory T cells in M. tuberculosis infection in a TLR2-dependent manner.
DISCUSSION
Rv0577, also known as CFP32, is one of the major culture filtrate (CF) proteins that have emerged as ϩ T cells and transgenic OVA-specific CD4 ϩ T cells were isolated, stained with CFSE, and cocultured for 96 h with DCs treated with Rv0577 (10 g/ml) or LPS (100 ng/ml), then pulsed with OVA 257-264 (1 g/ml) for OVA-specific CD8 ϩ T cells (A) or OVA 323-339 (1 g/ml) for OVA-specific potential candidates for the diagnosis and drug targeting of TB (14) . The gene encoding Rv0577 is found exclusively in the M. tuberculosis complex. Unlike other CF proteins, such as 85 Ag complex, Rv0577 is uniquely present in members of the M. tuberculosis complex and has not been identified in environmental mycobacteria (14) . Furthermore, transfer of the rv0577 gene into Mycobacterium smegmatis has recently been demonstrated by Andreu et al. (27) ϩ T cells (11) . In addition, M. tuberculosis Ags, such as Rv1196 and Rv1917c, were reported to strongly induce the secretion of IL-10, known to favor and drive Th2 immune response (13, 30) . Although many M. tuberculosis Ags have been discovered, little is known about M. tuberculosis Ags that induce Th1-polarized immune responses via DC maturation. Recently, the M. tuberculosis protein Rv0577 was detected in individuals infected with M. tuberculosis (14) , and previous work has reported the development of specific Rv0577 serum antibody-capture ELISAs for TB diagnosis (31) . Little is known, however, about the functional role of M. tuberculosis Rv0577 in the biology of M. tuberculosis. In this study, we show that M. tuberculosis Rv0577 induces DC maturation by augmenting the expression of CD80, CD86, and MHC class I and MHC class II molecules and produces markedly higher levels of proinflammatory cytokines, such as TNF-␣, IL-6, and IL-1␤. Furthermore, Rv0577 was found to significantly induce the secretion of IL-12p70, a Th1-polarizing cytokine, but not IL-10. IL-12 was previously reported to mediate the expression of proinflammatory cytokines, such as TNF-␣, IL-1␤, and IL-6, in DCs (32) , and when secreted by APCs is known to induce the secretion of IFN-␥ from T cells and to play a critical role in driving Thl immune responses (33) . Thus, our findings indicate that Rv0577 contributes to Th1 polarization of the immune response via DC maturation.
Cell-surface interactions are one of the most important events for the initiation of biological responses to extracellular stimuli. Among various cell-surface receptors, TLR2 is crucial in both the innate and adaptive immune responses of a host to microbial pathogens (8) and is known to play a pivotal role in the activation of inflammatory immune responses by M. tuberculosis Ags (34) . M. tuberculosis Ags, such as glycolipids and lipoproteins, were shown to stimulate macrophage and DC activation through TLR2, thus stimulating both CD4 ϩ and CD8
ϩ T lymphocytes (35) . Rv1818c was shown to interact directly with TLR2, thereby mediating apoptosis and cytokine secretion (36) . Rv0978c and Rv0754 were also shown to interact with TLR2, prompting maturation and activation of DCs (11) . In addition, lipomannan (LM) from several mycobacterial species was found to induce macrophage activation, which was characterized by TNF-␣ and nitric oxide secretion through TLR2 (37) . These findings suggest that TLR2 may play a significant role in regulating the cellular immune responses of M. tuberculosis. Thus, identification of novel TLR2 agonists is needed for use as adjuvants in infectious disease control and in the development of credible vaccine candidates. Although several M. tuberculosis Ags have been identified as TLR2 agonists and are known to regulate APC activation by modulating TLR2-mediated signaling, the underlying mechanisms of how the novel M. tuberculosis Rv0577 interacts with the cell surface are not understood. Here we show, for the first time, that Rv0577 directly interacts with cell surface TLR2 and induces DC maturation in a TLR2-dependent manner. In addition, we also show that Rv0577 significantly increases the expression of surface molecules and proinflammatory cytokine secretion by activation of the MAPK and NF-B pathways in DCs under MyD88-dependent signaling pathways. Thus, our findings indicate that Rv0577 is an agonist for TLR2 and that MyD88-mediated signaling is essential for an optimal, Rv0577-induced cytokine response by DCs. MyD88 was previously shown to act as an adaptor molecule essential for signaling of Ags via the TLR family (8) . Furthermore, signaling through MyD88 was reported to play a crucial role in host resistance associated with the regulation of mycobacterial-induced cytokine production (38) . Others have shown that MyD88-deficient APCs, like macrophages and DCs, display a marked reduction in the synthesis of IL-12, TNF-␣, and nitric oxide when exposed to M. tuberculosis (39) .
An important finding of this study was that the Rv0577 expressed in E. coli mediated TLR2 signaling. In general, TLR2 has been well documented to be recognized by lipidated Ags, including mycobacterial lipoproteins, such as LprA (Rv1280c) and LpqH (Rv3763), and glycolipids, such as phosphatidyl-(myo)-inositol mannosides (PIMs), lipomannans (LMs), lipoarabinomannans (LAMs), and inositol phosphate-capped LAMs (PI-LAMs). Although Escherichia coli lacks posttranslational modifications such as glycosylation and acylation, several mycobacterial proteins work as TLR2 agonists. For example, PE_PGRS33 expressed in E. coli triggers apoptosis in macrophages by directly interacting with TLR2 (36), and M. tuberculosis heat shock protein 60 expressed in E. coli modulates immune responses by interacting with TLR2 on macrophages (40) . Another study showed that early secreted Ag ESAT-6 of M. tuberculosis expressed in E. coli blocked TLR signaling by direct interaction with TLR2 (24) . Originally, M. tuberculosis LprG (Rv1411c) was known to require acylation to reflect TLR2 agonist activity (34) but nonacylated LprG retained TLR2 activity, suggesting that certain proteins of M. tuberculosis do not require lipidation for their TLR2 activity (41) . Thus, the acylation of Rv0577 is not required for TLR2 activity.
Another significant finding of our work was that Rv0577 induced Th1-polarized immune responses, which are thought to be critical to host protection against M. tuberculosis infection. Although TLR2-mediated immune responses of cell wall fractions and lipoproteins are essential for the induction of a protective immune response to mycobacteria (42) , several TLR2 agonists discovered in M. tuberculosis, including PE/PPE family proteins, LprA, and LprG, contribute to escape of the bacterium from host defenses. Rv1917c of M. tuberculosis (PPE34), for example, induces selective maturation of human DCs toward Th2 immune responses, with increased levels of IL-10 and lipoproteins (including LprA and LprG) and inhibits MHC II-mediated Ag processing of macrophages, resulting in a decrease in IFN-␥ production (13) .
T lymphocytes play a critical role in the control of a protective immune response in M. tuberculosis infection (43) . Under optimal Ag stimulation, DCs first take up Ags and then travel to the lymph nodes where they present processed Ags to naive T cells. These naive T cells are stimulated to proliferate and differentiate into functional effector and memory T cells, a subset of antigen-specific T cells (44) . These cells generally do not show direct action during an infection; instead, they enable the body to react quickly and control a recognized pathogen if encountered again (44) . Thus, the M. tuberculosis vaccine likely acts to affect the quality and quantity of memory T cells.
Recently, several studies have revealed that M. tuberculosis Ags induce the activation of CD4 ϩ and CD8 ϩ T cells through TLR-mediated DC activation. This is thought to lead to protective immunity against M. tuberculosis by triggering IFN-␥ production, which plays a particularly important role in the activation of antigen-presenting cells in CD4 ϩ and CD8 ϩ T cells (12, 13) . Based on this, CD4 ϩ and CD8 ϩ T cells have been suggested to play a protective role in immune responses against infection. Notably, we showed that Rv0577 enhances the ability of DCs to stimulate naive T cells and that Rv0577-matured DCs trigger IFN-␥ and IL-2 production in CD4 ϩ and CD8 ϩ T cells. In addition, we also found that Rv0577-treated DCs up-regulated CXCR3 expression in CD4 ϩ T cells, whereas CCR3 expression remained at baseline levels, indicating Rv0577 participated in adaptive immunity by directing T cell immune responses to a Thl polarization.
Protection against TB depends on the rapid generation of effector memory T cells capable of producing IFN-␥. These cells are believed to be central components of acquired immunity and are the basis for successful vaccination against TB (43) . Furthermore, antigen-bearing DCs regulate the diverse pattern of effector memory CD4 ϩ /CD8 ϩ T cell development in different tissues (45) . After M. tuberculosis infection, CD4 ϩ and CD8 ϩ T cells expand into effector cells and then differentiate into long-lived memory cells (46) . Evidence that these cells potently and specifically inhibit the growth of the intracellular bacteria M. tuberculosis has been shown in vitro, whereby they displayed macrophage antimycobacterial activity, and in vivo, when they promote the survival of infected mice (47) . Furthermore, these cells expand in the spleens of mice infected with M. tuberculosis (47) . The findings have significant implications for the design of vaccines and immunization strategies for the protection against M. tuberculosis infection.
In general, effector memory T cells are known to express the CD44 high CD62L low surface phenotype. CD44 is a surface protein required for lymphocyte extravasation to inflammatory sites and its up-regulation is a marker for all memory T cells (48) . CD62L is a lymph node homing receptor that is down-regulated on activation of T-cell populations (49) . In murine models of M. tuberculosis and M. bovis infection, accumulation of CD4 ϩ T cells with decreased CD62L and increased CD44 expression at the site of infection has been reported (50) . Also, IFN-␥ producing cells have been described as bearing a CD44 high and CD62L low phenotype (50) .
In our work, we demonstrated that a population of CD44 high CD62L low CD4 ϩ /CD8 ϩ effectors was specifically generated from splenic T cells of M. tuberculosisinfected mice in response to DC-bearing Rv0577, indicating that Rv0577 acts as a specific recall antigen. In this regard, Rv0577 could be a potent adjuvant trigger-ing Th1-mediated immune responses. In addition, TLR2 has a particularly important role in the maintenance of memory Th1 responses in M. tuberculosis infection. In addition, the use of TLR2 agonists as T-cell antigens in TB vaccines may be important, since these molecules may directly enhance CD4 ϩ /CD8 ϩ T-cell memory responses and thus confer protective immunity against M. tuberculosis (51). Since our study focused on murine DCs in vitro, and the TB model for humans is different from the murine model in the aspect of the pathogenesis and immunological events, further work will be needed to extend these findings to human DCs from individuals infected with M. tuberculosis.
Nevertheless, these findings conclusively demonstrate that the Rv0577 plays a critical role in the activation of DCs in a TLR2-dependent manner and the initiation of the adaptive immune response by polarizing the development of T cells to a Th1 response. These novel findings about the role of the Rv0577 will be useful in the design of new strategies to prevent many chronic diseases caused by M. tuberculosis.
